Novo's Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First
CompanyDrug

Novo’s Kyinsu Wins EU Approval for Type 2 Diabetes, a Once-Weekly Combo First

Novo Nordisk's Semaglutite Alzheimer's Failure Sends Stock to 4-Year Low
CompanyDrug

Novo Nordisk’s Semaglutite Alzheimer’s Failure Sends Stock to 4-Year Low

Zelgen's ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific
CompanyDrug

Zelgen’s ZG006 Wins BTD for Neuroendocrine Carcinoma as First DLL3 Trispecific

Hengrui's Ivarmacitinib NDA Accepted for Non‑Radiographic Axial Spondyloarthritis
CompanyDrug

Hengrui’s Ivarmacitinib NDA Accepted for Non‑Radiographic Axial Spondyloarthritis

AstraZeneca's Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy
CompanyDrug

AstraZeneca’s Durvalumab Wins China Approval for Stage III NSCLC After Sequential Chemoradiotherapy

Qihan-Biotech's QT-019B Universal CAR-T Wins Implied NMPA Approval
CompanyDrug

Qihan-Biotech’s QT-019B Universal CAR-T Wins Implied NMPA Approval

Junshi's JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC
CompanyDrug

Junshi’s JS001sc Subcutaneous PD-1 Meets Phase 3 Endpoint in NSCLC

Rimag Partners with Qingyang Government on AI Medical Imaging Infrastructure
CompanyDeals

Rimag Partners with Qingyang Government on AI Medical Imaging Infrastructure

Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides
CompanyDeals

Biogen Dayra Partnership Targets Immunology with Macrocyclic Peptides

CStone's Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication
CompanyDrug

CStone’s Sugemalimab Wins EU Approval for Stage III NSCLC, Expanding European Indication

Salubris' SAL0139 Wins NMPA Nod for Hyperlipidemia Clinical Trial
CompanyDrug

Salubris’ SAL0139 Wins NMPA Nod for Hyperlipidemia Clinical Trial

Zhongsheng's Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient
CompanyDrug

Zhongsheng’s Onradivir Granules Enroll First Phase 3 Pediatric Influenza Patient